Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2003

Filing Date
Filed February 20, 2004
Period End
December 31, 2003
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 20, 2004. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (filed under this name; now trading as EXEL on Nasdaq) reported a net loss of $94.8 milliona for the year ended December 31, 2003, on total revenues of $51.5 million, compared with a net loss of $86.1 million and revenues of $44.3 million in 2002.

Research and development expense rose to $127.6 millionb from $112.0 million, and the accumulated deficit reached $382.1 million. The company states it expects losses to continue and anticipates negative operating cash flow for the foreseeable future. Cash, cash equivalents, short-term investments and restricted cash and investments totaled $241.9 million at December 31, 2003, which management says will support currently planned operations for at least the next two years.

The company's pipeline is led by XL119, a rebeccamycin analogue for which it plans to start a Phase 3 trial for bile duct tumors in the second quarter of 2004. XL784, an ADAM-10 metalloprotease inhibitor, is in Phase 1 trials, and IND filings are planned for XL647 (first quarter of 2004), XL999 (second quarter of 2004) and XL844 (early 2005). Revenue depends heavily on collaborators, with three partners accounting for approximately 31%c, 28% and 21% of 2003 revenue.

Key partners include GlaxoSmithKline, Bristol-Myers Squibb, Bayer and Dow AgroSciences. The filing also details the company's dependence on collaborations, third-party manufacturing, and patent protection, and notes a 2003 restructuring of its research organization that included a reduction in force of 61 research personnel and the closure of its Tübingen, Germany facility. Management also disclosed that its former Chief Scientific Officer left at the end of 2003.

Key Highlights

  1. Net loss of $94.8 million for 2003, up from $86.1 million in 2002; accumulated deficit of $382.1 million.
  2. Total revenues of $51.5 million in 2003, up from $44.3 million in 2002, driven mainly by the October 2002 GlaxoSmithKline collaboration.
  3. Research and development expense of $127.6 million in 2003, compared with $112.0 million in 2002.
  4. Cash, cash equivalents, short-term investments and restricted cash and investments of $241.9 million at December 31, 2003, expected to fund planned operations for at least two years.
  5. Lead compound XL119 is planned to enter Phase 3 trials in the second quarter of 2004 for bile duct tumors; XL784 is in Phase 1.
  6. Three collaborators accounted for approximately 31%, 28% and 21% of 2003 total revenue, showing concentration risk.
  7. Convertible promissory loans from GlaxoSmithKline ($55.0 million) and Protein Design Labs ($30.0 million) were outstanding at year-end 2003.

Frequently Asked Questions

  1. Why did the net loss increase in 2003?

    Research and development expense rose by $15.6 million to $127.6 million, which the filing attributes to personnel, lab supplies, consulting for clinical and preclinical programs, and facilities expansion. Revenue growth of $7.2 million only partly offset these costs.

  2. How long will the company's cash last?

    The company states that its cash, cash equivalents, short-term investments and funding from current collaborators will enable it to maintain currently planned operations for at least the next two years, though it may need to raise additional capital sooner if its operating plan changes.

  3. What are the main near-term pipeline milestones?

    The company plans to start a Phase 3 trial of XL119 in the second quarter of 2004 and expects to file IND applications for XL647 in the first quarter of 2004, XL999 in the second quarter of 2004, and XL844 in early 2005.

  4. How concentrated is the company's revenue?

    Revenue is concentrated among collaborators. In 2003, three collaborators represented approximately 31%, 28% and 21% of total revenue, and the company says substantially all revenue to date has come from collaborative agreements.

  5. What did the 2003 restructuring involve?

    In the third quarter of 2003 the company reduced research personnel by 61 in South San Francisco and Tübingen, closed its Tübingen facility, and moved some activities to South San Francisco. It recorded a charge of approximately $925,000 in 2003 and expected about $1.3 million of additional expenses through the first quarter of 2004.